Recent Headlines
AnaSpec Introduces GO Peptides™ - Research-Ready Peptides on Demand
AnaSpec is pleased to introduce GO Peptides™, the next evolution in peptide tools. - August 13, 2008 - AnaSpec, EGT Group
AnaSpec Introduces New SensoLyte™ 570 Generic MMP Assay Kit with Industry’s Highest Wavelength
Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated proteins capable of digesting extracellular matrix components. The importance of MMPs in tumor development and invasion as well as other diseases is well known. AnaSpec has introduced the SensoLyteTM 570 Generic... - August 09, 2008 - AnaSpec, EGT Group
Novus Biologicals and AnaSpec Sign Licensing Agreement for HiLyte™ Dyes
AnaSpec and Novus Biologicals today announced a licensing agreement that will allow Novus Biologicals to label Novus antibodies with AnaSpec HiLytePlus™ and HiLyte Fluor™ dyes. HiLytePlus™ and HiLyte Fluor™ are AnaSpec's proprietary series of high performance fluorescent... - July 30, 2008 - AnaSpec, EGT Group
AnaSpec Offers Custom Peptide-Aminoluciferin Synthesis
AnaSpec now offers custom synthesis service of peptide-aminoluciferin substrates. - July 23, 2008 - AnaSpec, EGT Group
AnaSpec Introduces New Series of PAR Peptides
AnaSpec has introduced its latest series of PAR peptides. - July 09, 2008 - AnaSpec, EGT Group
New Anti-Keratin Antibodies Introduced by AnaSpec
AnaSpec has introduced two keratin antibodies that recognize both the intact and caspase digested N-terminal of K18 and K19 at Asp237. These antibodies are useful tools for studying keratin dynamics in mice undergoing hepatocyte apoptosis, patients with cirrhosis, and also in apoptotic cells of... - July 04, 2008 - AnaSpec, EGT Group
New SensoLyte HDAC Assay Kit Introduced by AnaSpec
Histone deacetylase (HDAC) enzymes modulate gene expression through the deacetylation of lysine residues on histone proteins and act as transcriptional repressors of genes. Based on their role in cell cycling, apoptosis and differentiation, HDACs have been chosen as therapeutic targets for the... - June 27, 2008 - AnaSpec, EGT Group
Xcelience Strengthens Development Services with Addition to Executive Team
The formulation development company’s services are led by an industry pioneer. - June 22, 2008 - Xcelience, LLC
AnaSpec Offers Custom Synthesis of Hydrocarbon-Stapled Peptides
The innovative technique of hydrocarbon stapling in peptides is introducing valuable new functionality to peptide-related research. AnaSpec is pleased to offer custom synthesis for hydrocarbon-stapled peptides. Hydrocarbon-stapled peptides are peptides capable of forming stable alpha helical... - June 20, 2008 - AnaSpec, EGT Group
New Anti-CARMA Antibody Series Released by AnaSpec
AnaSpec has introduced a new series of IHC validated antibodies, Anti-CARMA/CARD/Bimp antibodies. CARMA proteins are scaffold molecules that belong to the membrane-associated guanylate kinase-like (MAGUK) and the caspase-associated recruitment domain (CARD) protein families. They play critical... - June 19, 2008 - AnaSpec, EGT Group
AnaSpec Introduces Eleven New Peptides
This week AnaSpec, a world leader in custom and catalog peptides, introduced eleven (11) new peptides. - June 18, 2008 - AnaSpec, EGT Group
Genomic Nanosystems Announced Today That It Has Received the Exclusive Patent Rights for Clonal Amplification and Digital PCR (Polymerase Chain Reaction) from Cytonix
Genomic Nanosystems, LLC has received the exclusive patent rights to U.S. patent No. 6,143,496. Patent ‘496 was first to describe methods for detecting single nucleic acid molecules after one amplification step, for amplifying one or more nucleic acids in nano-scale volumes or regions, and for carrying out digital PCR. - June 01, 2008 - Genomic Nanosystems
New SensoLyte™ 520 Cathepsin S Assay Kit Introduced by AnaSpec
AnaSpec has introduced the SensoLyte™ 520 Cathepsin S Assay Kit to its broad collection of long wavelength FRET protease assay kits. - May 29, 2008 - AnaSpec, EGT Group
AnaSpec Introduces Sixty New Peptides & 3 New Assay Kits
This week, AnaSpec introduced sixty (60) new catalog peptides and three (3) new assay kits. - May 27, 2008 - AnaSpec, EGT Group
Xcelience and Its CEO Are Finalists for Three Prestigious Business Awards
The Tampa-based CRO and its chief executive are voted as best company and CEO of the year. - May 26, 2008 - Xcelience, LLC
AnaSpec Introduces 8 New Antibody Products
AnaSpec added eight (8) new antibody products to its growing collection. - May 24, 2008 - AnaSpec, EGT Group
AnaSpec Introduces ClearPoint™ Heavy Isotope-Labeled Peptides
AnaSpec has introduced ClearPoint™ Peptides, heavy isotope-labeled peptides for absolute quantitation (AQUA) of proteins. - May 18, 2008 - AnaSpec, EGT Group
Xcelience Launches New Service to Enhance Its Preformulation & Formulation Capabilities
The Tampa-based CRO continues its perpetual growth with new XRD support. - May 08, 2008 - Xcelience, LLC
AnaSpec’s Published References Passes 600
The number of published papers that cite AnaSpec’s products has passed 600. - May 04, 2008 - AnaSpec, EGT Group
AnaSpec Presents Fluorimetric TACE Detection Poster at SBS Conference
AnaSpec presented its latest findings in regards to the detection of TACE activity using FRET technology. - May 03, 2008 - AnaSpec, EGT Group
AnaSpec Introduces a Suite of Phospho-Specific Anti-Her2 Antibodies
AnaSpec has introduced a full suite of phospho-specific ErbB-2 (Her-2) polyclonal antibodies. - April 30, 2008 - AnaSpec, EGT Group
AnaSpec Introduces 13 New Antibody Products
AnaSpec added thirteen (13) new antibody products to its growing collection. - April 25, 2008 - AnaSpec, EGT Group
SensoLyte™ MMP Assay Kits Offer a New Industry Standard for Sensitivity
AnaSpec’s SensoLyte™ line of MMP assay kits have quickly become the new standard in MMP assay sensitivity. - April 24, 2008 - AnaSpec, EGT Group
AnaSpec FRET-Based MMP Substrates Used in Double Differential in Vivo Zymography
AnaSpec FRET-based MMP substrates were recently used in a double differential in vivo zymography study at the University of New Brunswick. - April 23, 2008 - AnaSpec, EGT Group
New Anti-MMP Antibodies Introduced by AnaSpec
AnaSpec has introduced its newest MMP antibodies. - April 11, 2008 - AnaSpec, EGT Group
AnaSpec Offers Fluo-3 - a High Affinity Fluorescent Calcium Indicator
Calcium plays a vital role in the specific and selective regulation of major cellular processes and is central in the regulation of cardiac contractility, growth and gene expression. Calcium indicators are small molecules that can respond to the binding of Ca2+ ions by changing their spectral... - March 29, 2008 - AnaSpec, EGT Group
AnaSpec Introduces Suite of Labeled & Unlabeled Anti-Actin Antibodies
AnaSpec has introduced a suite of labeled and unlabeled anti-Actin antibodies. - March 26, 2008 - AnaSpec, EGT Group
AnaSpec Introduces New Technical Support Solution
This month AnaSpec introduced a significantly improved online technical support resource for its website users. AnaSpec's new Frequently Asked Questions (FAQ) Page now offers a searchable database of solutions that offers a more convenient and more comprehensive solution for technical support needs. - March 22, 2008 - AnaSpec, EGT Group
AnaSpec Introduces Phosphopeptide Standards Kit
AnaSpec has introduced a dependable tool for the analysis and characterization of phosphorylated peptides – AnaSpec’s Phosphopeptide Standards Kit. - March 19, 2008 - AnaSpec, EGT Group
AnaSpec Introduces 58 New Antibody Products
Continuing to rapidly expand its antibody offerings, AnaSpec has added fifty-eight (58) new antibody products to its growing collection. Anti-PTEN (pSer385) (polyclonal) - Cat# 29642-025, 25 µg Host: rabbit polyclonal; Species Reactivity: human; rat; mouse; Applications: IP; WB;... - March 16, 2008 - AnaSpec, EGT Group
NCSRT Launches DiaSync for Improved Yield, Lower Cost in Harvest, Concentration, and Diafiltration of Biomolecules
At the Antibody Development and Production meeting in San Diego, CA March 12, 2008, NCSRT is launching its DiaSync process for biomolecules from fermentation, cell culture, or extraction. Utilizing concurrent processing technology and the patented SmartFlow™ TFF technology, DiaSync provides... - March 12, 2008 - NCSRT, Inc.
AnaSpec Introduces New SensoLyte™ Cathepsin D Activity Assay Kits
AnaSpec has introduced a new series of SensoLyte™ Cathepsin D Activity Assay Kits to address the issue of autofluorescence interference. - March 09, 2008 - AnaSpec, EGT Group
AnaSpec Introduces Two Novel Amino Acids
AnaSpec has introduced two novel amino acids that offer additional tools and functionality for peptide chemists. - March 05, 2008 - AnaSpec, EGT Group
AnaSpec Introduces 9 New Antibody Products
AnaSpec added nine new antibody products to its growing collection. - February 28, 2008 - AnaSpec, EGT Group
Former Manchester City Lord Mayor Has Hope and Quality of Life Restored at New Beike Stem Cell Facility
Shenzhen Beike Biotechnology Co., Ltd. (http://www.beikebiotech.com), the world leader in the use of umbilical cord stem cells to successfully treat a variety of illnesses, announced that Audrey Jones, the former Lord Mayor of Manchester, has returned today to the United Kingdom (UK) with... - February 26, 2008 - Shenzhen Beike Biotechnology Co., Ltd.
AnaSpec Introduces 5 New Peptide Synthesis Reagents
AnaSpec added five (5) new peptide synthesis reagents to its combinatorial chemistry collection. - February 24, 2008 - AnaSpec, EGT Group
AnaSpec Introduces Collection of Channel Blocker Peptides
AnaSpec has introduced its selection of channel blocker peptides. - February 21, 2008 - AnaSpec, EGT Group
AnaSpec Introduces New Suite of Fluorescently Labeled GST & 6xHis Tag Antibodies
AnaSpec has introduced a suite of fluorescently labeled GST and 6X-His antibodies. These antibodies are labeled with a selection of dyes, including AnaSpec’s proprietary HiLyte FluorTM and HiLytePlusTM dyes, which span the visible spectrum. This gives researchers a wide range of wavelength... - February 16, 2008 - AnaSpec, EGT Group
AnaSpec Introduces 46 New Antibody Products
Continuing to rapidly expand its antibody offerings, AnaSpec added forty-six (46) new antibody products to its growing collection. Anti - GST Tag AMCA labeled - Cat# 29531-AMCA, 100 µg Host: mouse monoclonal; Application: IHC Anti - GST Tag Biotin labeled - Cat# 29531-BIOT, 100... - February 13, 2008 - AnaSpec, EGT Group
AnaSpec Introduces 21 New Anti-Tau Antibodies
AnaSpec has announced the release of 21 new anti-Tau antibodies. Complementing one of the world’s most comprehensive collections of beta-amyloid peptides, this new selection of anti-Tau antibodies demonstrates AnaSpec’s efforts to deliver new solutions for Alzheimer research. Tau is a... - February 11, 2008 - AnaSpec, EGT Group
NCSRT Presents SmartFlow™ TFF Performance Advantages Over Centrifugation and Microfiltration for Monoclonal Antibody Recovery, Concentration and Diafiltration
NCSRT is presenting “A comparison of product yield using either centrifugation and microfiltration or simultaneous membrane processing with SmartFlow™ TFF” at the Waterside Conference in Miami, FL. The data, generated by Viventia Biotech of Winnipeg, Manitoba, Canada, demonstrates... - February 08, 2008 - NCSRT, Inc.
AnaSpec Introduces 9 New Antibody Products
Continuing to rapidly expand its antibody offerings, AnaSpec added nine (9) new antibody products to its growing collection. Anti-AKT pan (IN) - Cat# 54320, 50 µg Host: rabbit polyclonal; Species Reactivity: human; mouse; rat; bovine; zebrafish; Applications: WB Anti-AKT pan (NT) - Cat#... - January 27, 2008 - AnaSpec, EGT Group
Xcelience Expands Its Early Drug Development Capabilities
The Tampa-based CRO is first to acquire next generation Xcelodose. - January 26, 2008 - Xcelience, LLC
AnaSpec Announces a Broad Selection of T-Cell Epitopes
AnaSpec has announced the availability of a wide selection of T-Cell Epitopes, available both individually and pooled. - January 23, 2008 - AnaSpec, EGT Group
Samaritan Pharma Strategically Advances Its Promising Alzheimer's Drug
Enters Service Agreement with Advinus Therapeutics, India to Validate Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol. Strategy is to Bolster Caprospinol Alzheimer's Data Package to Out-License to Big Pharma and Expand IND Application to Enter Human Trials. Samaritan... - January 09, 2008 - Samaritan Pharmaceuticals
Samaritan Announces the Granting of European Patent for New Type of Cardiovascular Plaque Clearing Drug SP-1000
Samaritan Pharmaceuticals has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease. - January 09, 2008 - Samaritan Pharmaceuticals
Three Rivers Adds Territory of Ireland to Samaritan's Existing Exclusive Licensing Agreement to Market Amphocil in Greece and Cyprus
Samaritan has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 09, 2008 - Samaritan Pharmaceuticals
Samaritan Pharmaceuticals Welcomes Two New Independent Directors to Its Board
Samaritan has appointed two new independent members, Jack L. Ayala and Robert W. Crane, to its Board of Directors. Mr. Ayala and Mr. Crane bring valuable experience and their appointment strengthens Samaritan's commitment to maintain a majority of independent members that reflects today's best practices on its Board. Samaritan's board is now comprised of eight independent directors and two internal directors. - January 09, 2008 - Samaritan Pharmaceuticals
AnaSpec Introduces Ten New Catalog Peptides
This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced ten (10) new catalog peptides and one new unusual amino acid. MSL8; [Met256]-OVA (257-264)- Cat# 62573-5 Sequence: MSIINFEKL MSL8; [Met256]-OVA (257-264)- Cat# 62573-1 Sequence: MSIINFEKL OVA... - January 04, 2008 - AnaSpec, EGT Group
FDA Accepts Samaritan's Cushing's SP-6300 IND and Clears Phase II Study
The U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism. - January 04, 2008 - Samaritan Pharmaceuticals